Oncoinvent ASA Reports Mandatory Trade Notification
Oncoinvent ASA has issued a mandatory notification of trade and shareholding disclosure following a private placement.
Oslo, 30 September 2026 – Oncoinvent ASA has issued a mandatory notification of trade and shareholding disclosure related to a private placement and retail offering completed on 22 September 2026. A total of 1,650,000 new shares were subscribed at a price of NOK 90 per share.
The notification also refers to a mandatory disclosure published on 23 September 2026 regarding the allocation of new shares and temporary lending of shares to Hadean Capital I AS, HVentures Capital I AB, and Hadean Growth Fund I AS.
These entities had temporarily lent shares in connection with the private placement. The company has now announced the return of these lent shares.
The share offering was conducted to raise capital for the company's development of cancer therapies. Oncoinvent focuses on advancing its treatments through clinical trials.